COVID-19 studies for: C19 studies:  HC QHC Q IvermectinIVM Vitamin DVitamin D ZincZn REGN-COV2REGN LY-CoVLY RemdesivirRMD
HC Q study #178
Source   PDF   Share   Tweet
See all 181 studies
11/20
Negative
Early treatment study
Omrani et al., EClinicalMedicine, doi:10.1016/j.eclinm.2020.100645 (Peer Reviewed)
Randomized double-blinded placebo-controlled trial of hydroxych loroquine with or without azithromycin for virologic cure of non-severe Covid-19
Low risk patient RCT for HC Q+AZ and HC Q vs. control, not showing any significant differences.
Authors note that the results are not applicable to higher risk patients; that positive PCR may simply reflect detection of inactive (non-infectious) viral remnants; that an alternative dosage regimen may be more effective; and that medication adherence was unknown.
HC Q dosing was 600mg/day for 1 week, therapeutic levels may not be reached for several days. There were no deaths or serious adverse events.
hospitalization, ↓12.5%, p=1.00, HCQ+AZ or HCQ vs. control risk of hospitalization
no recovery, ↓25.8%, p=0.58, HCQ+AZ or HCQ vs. control risk of symptomatic at day 21
no virological cure, ↑10.3%, p=0.13, HCQ+AZ or HCQ vs. control risk of Ct<=40 at day 14
Source   PDF   Share   Tweet
See all 181 studies
Please send us corrections, updates, or comments.
Submit